PMID

Data

Article Title

Organization

Recent Progress in Histone Demethylase Inhibitors.

University Of Oxford

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.

The Institute Of Cancer Research

KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.

National Tsing Hua University

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.

University Of Oxford

Recent Advances with KDM4 Inhibitors and Potential Applications.

St. Jude Children'S Research Hospital

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).

Hangzhou Normal University

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.

Institute Of Cancer Research

Structure-based design and discovery of potent and selective KDM5 inhibitors.

Celgene

Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.

Abbvie

Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

Celgene Quanticel Research